All News

Article

Will AI put me out of a job?

Adela Castro, MD Feb 11, 2025

The development of AI and other technologies brings new possibilities for optimizing diagnosis, management and has potential for improving outcomes in RA. At RheumNow Live 2025, Dr. Jeff Curtis, University of Alabama at Birmingham, presented a talk on, "AI applied to Rheumatoid Arthritis Care: Practically (Not) Perfect".

Article

Obinutuzumab Efficacy in Active Lupus Nephritis

Jack Cush, MD Feb 10, 2025

A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.

Article

“Preventing” Arthritis in Psoriasis

Richard Conway, MBBChBAO, PhD Feb 10, 2025

The always compelling Dr. Alexis Ogdie explored whether aggressive treatment of psoriasis can prevent psoriatic arthritis in an excellent Saturday morning session at RheumNow Live 2025.

Eric Dein @ericdeinmd 🏈Kick-off of @RheumNow w Jeff Curtis #RNL2025 🏈 AI in RA? Can help with Rheum Boards Questions, though AI is not confident in answers May not be better than paper charts for triage Other roles: pt chatbot, AI scribe, research populations, generate DDx,… https://t.co/3vJ2gON6tR https://t.co/3ArtaRkhJp

TheDaoIndex @KDAO2011 Potential uses of #AI for #RA -office workflow (scribe, triage) -research (match eligible pts for trials) -help with diagnosis (and likelihood of risk) -consume guidelines for disease mgmt @RADoctor #RNL2025 https://t.co/k2nOytpKBH https://t.co/7Y2OvBv9pP

https://buff.ly/3CxU9hW

QD Clinic - Recurrent Acute Oligoarthritis Recurrent Acute Oligoarthritis in a 40 yr. old man https://t.co/5D5qE05u1w https://t.co/tunU955MkH

QD Clinic - Recurrent Acute Oligoarthritis | RheumNow

Cannabis Hospitalizations and Mortality Risk A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death. https://t.co/MQtR3etpEH https://t.co/ZB4byi81on

Cannabis Hospitalizations and Mortality Risk | RheumNow

SLE subphenotypes predisposed by distinct genetic risk loci. Multicenter 10 yr genotyping study on 1462 SLE pts (56% w/ lupus nephritis & 43% not LN) found significantly higher polygenic risk scores (PRS); significant LN variants included HLA, TNFAIP3, BLK, & STAT4.… https://t.co/5igpgtdE1U https://t.co/5KOXRThzlk

Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o

https://buff.ly/416zZF0

Dr Cather treatment options in HS. The last 2 obviously in rheumatology's wheelhouse @RheumNow #RNL2025 https://t.co/vGfvQH05lv

https://x.com/RichardPAConway/status/1888592438958358864/photo/1

New for HS - Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2 - Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE) Clinical trials: IL23 failed, ILalpha failed Brodulamab (IL17a) clinically meaningful response TNF trials @RheumNow #ACR2025 https://t.co/BfzwNQ1wUB

The ‘dark’ side of #Hidradenitis #suppurativa 👇 Smell of leaking lesions #HS ⬆️skin folds, buttock, axilla, also thighs, neck ⬆️depression @RheumNow #RNL2025 ‘ If pt doesn’t get in gown then not ready for systemic #Rx!’ Jennifer Clay #ClinicalPearl https://t.co/tZzz5tielt

-HS ttx👇 1. Lifestyle changes: smoking cessation, obesity. 2. Management of comorbidities. 3. 🔍HS- related autoimmune disorders. 4. FDA approved biologics: -Adalimumab (PIONEER 1&2) -Secukinumab (SUNRISE, SUNSHINE) -Bimekizumab (BE HEARD 1&2) "Theres no such… https://t.co/G5Voxrm3Kt https://t.co/dLGtoFZMd1

1/3 of #axial #PsA 👇 No #SI joint changes , only #axial ⁦@RheumNow⁩ #RNL2025 Catherine Blackwell #ClinicalPearl https://t.co/YmoipL1bME

https://x.com/Janetbirdope/status/1888596259570610338/photo/1

Pregnancy is 🔥 inflammatory Hard to interpret MRI of SI joints in setting of pregnancy Ideally, don't score MRI during pregnancy or 1 year afterwards, would be affected by the pregnancy If needed for clinical eval, focus on structural lesions like erosions #RNL2025 @RheumNow

Full read review and overview of Fibromyalgia - manifestations, pathophysiology, treatments and guidelines. Multidisciplinary, patient-centered treatment should includes a combination of pharmacological and nonpharmacological options. https://t.co/x4OVeQ5RJz https://t.co/i1fD6XQbnx

Fibromyalgia: Understanding, Diagnosis and Modern Approaches to Treatment

P2 Trial: DEU in PsA Encouraging results for DCV 6 and 12 mg qd. ACR20 63% for DCV 12 mg (p=0.0004) Not yet FDA approved for PsA, only PsO Pending P3 P2: DEU in SLE - PAISLEY Improved SRI(4), CLASI-50 at w32 Merola #RNL2025 @RheumNow https://t.co/RV7OPaZWjx

Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95

https://x.com/RichardPAConway/status/1888326939146092638/photo/1

MDA5 + Pts with #ILD in #dermatomyositis can improve! ⁦@RheumNow⁩ ⁦@ACRheum⁩ #RNL2025 Data from Christina Charles-Schoeman #ClinicalPearl Her pearls 👇 #DM is a #vascular #disease #CK is not reliable in chronic DM Neg Abs don’t r/o #myositis https://t.co/hxomz70aq5

https://x.com/Janetbirdope/status/1888329077494317407/photo/1

#RNL2025 @RheumNow Dermatomyositis is VASCULAR disease -IVIG may help DM by blocking complement deposition on endomysial capillaries -CK levels not reliable Pruritus common in up to 86% of DM patients Dr. Charles-Schoeman, UCLA

Topics

All News

Will AI put me out of a job?

Obinutuzumab Efficacy in Active Lupus Nephritis

“Preventing” Arthritis in Psoriasis

Do you get our email newsletter?